Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
Date:5/19/2008

oid Receptor Allow

IL-13 Zetakine Transgenic CTLs to Kill Glioblastoma Cells in vivo in

the Presence of Immunosuppressing Glucocorticoids" Philip Gregory, D.

Phil., Vice President, Research, Sangamo BioSciences, Inc.

-- Monday, May 19:

-- Workshop: "Emerging Technologies" Bruce Levine, Ph.D., Department

of Pathology and Laboratory Medicine, University of Pennsylvania

School of Medicine.

-- Poster Session: "Controlling HIV in vivo - Establishment of HIV

Resistant CD4 T Cells by Engineered Zinc Finger Protein

Nucleases."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF)(TM) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN)(TM) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
2. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
3. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
4. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
5. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
6. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
9. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
10. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
11. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... AB, the Swedish,life science technology company, has ... based on supercritical fluid technology.,The Company,s RightSize ... of traditional micronization and is well suited ... the advantages of earlier supercritical,fluid technologies it ...
... As researchers push towards detection of single molecules, single ... movement, Yale researchers have demonstrated silicon-based nanocantilevers, smaller than ... eliminating the need for electric transducers and expensive laser ... advance online publication of Nature Nanotechnology ushers ...
... CITY, China, April 24 Sinobiopharma, Inc. (OTC Bulletin ... highlights from the unaudited financial results for the nine month period ... , Sales revenue increased to ... US $1,170,677 in the corresponding period ended February 29, 2008. ...
Cached Biology Technology:Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 2Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 3Catching the lightwave: Nano-mechanical sensors 'wired' by photonics 2Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009 2
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
(Date:4/17/2014)... One day about eight years ago, Katia ... Riverside, and her father were on a field trip in ... an orchid they had never seen before. , Unable to ... orchids. The orchid turned out to be an unnamed ... Lophiaris silverarum . , "Lophiaris" is the genus name, comprising ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... a current issue in neuroscience, Aldo Faisal and Simon Laughlin ... transmitting information. They show that noise effects in ion channels ... the fidelity of transmission is compromised. , Neurons in ... density of up to 4km per mm3 by using incredibly ...
... A naturally occurring molecule in the body appears to ... agonists used in acute heart failure or in inhalers ... oxide is a molecule produced by the body that ... blood vessels. , New experiments conducted by Duke ...
... The first clinical trial to test a revolutionary treatment ... at UCL (University College London). The trial, funded by ... kind and could have a significant impact on future ... involves adults and children who have a condition called ...
Cached Biology News:Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3First clinical trial of gene therapy for childhood blindness 2
... Sample Preparation for Membrane Proteins ,Contains ... membrane,protein extracts for 2-D gel analysis ... Extraction Kit , (contains sufficient ... a packed cell weight of 10 mg ...
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
Biology Products: